icon caret-left icon caret-right instagram pinterest linkedin facebook twitter goodreads question-circle facebook circle twitter circle linkedin circle instagram circle goodreads circle pinterest circle

Genetic Linkage

A 31-Gene Test to Predict Alzheimer’s

When the direct-to-consumer genetic testing company 23andMe received FDA approval back in April to market a test for the e4 variant of the gene APOE, which is associated with elevated risk of developing late-onset Alzheimer’s disease, it gave people a possible peek into their futures.

About 15 percent of the population has one or two copies of the high-risk gene variant. For a long time the risk of developing Alzheimer’s for e4 double-dose individuals was 12 to 15 fold, but only 3 fold for those with one copy. Those figures have declined with re-analysis of the data.

A new 31-gene test can identify individuals at higher risk for the disease, including many who test okay for APOE e4. (Which stands for "apolipoprotein E epsilon 4 allele.")

A MORE POWERFUL TEST Read More 
Be the first to comment

Jim Watson at International Congress of Human Genetics

Montreal, Oct. 11, 2011 -- James Watson joined a panel of “genome pioneers” at the opening session of the 12th International Congress of Human Genetics today. He was invited, besides his fame, because he was the second person to have his genome sequenced (Craig Venter was first), but his comments revealed that perhaps his most telling qualification is that he has a son who has schizophrenia. Known for his controversial views, Dr. Watson did not disappoint.  Read More 
3 Comments
Post a comment